[肺癌中的抗血管生成：现状、进展与困惑]
[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].
作者信息
Jiang Zhou, Chen Jianhua
机构信息
Department of Thoracic Medicine, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha 410006, China.
出版信息
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):278-286. doi: 10.3779/j.issn.1009-3419.2022.101.16.
Abstract
Lung cancer is a highly vascular tumors, over the past ten years, anti-angiogenes is has been proved to be an effective and highly promising combinational treatment. The data of the combination of anti-angiogenesis with chemotherapy, targeted therapy, immunotherapy has been constantly updating. Advanced lung cancer patients, no matter different groups or different stages of the disease, are benefited from anti-angiogenes. In this paper, based on the clinical status and unsolved problems, combined with the latest clinical and translational research data, we reviewed the current anti-angiogenesis treatment of lung cancer. .
摘要
肺癌是一种血管丰富的肿瘤，在过去十年中，抗血管生成疗法已被证明是一种有效且极具前景的联合治疗方法。抗血管生成与化疗、靶向治疗、免疫治疗联合应用的数据一直在不断更新。晚期肺癌患者，无论疾病的不同分组或不同阶段，都从抗血管生成治疗中获益。本文基于临床现状和未解决的问题，结合最新的临床和转化研究数据，对目前肺癌的抗血管生成治疗进行综述。
相似文献
1
[Anti-angiogenesis in Lung Cancer: Current Situation, Progress and Confusion].[肺癌中的抗血管生成：现状、进展与困惑]
Zhongguo Fei Ai Za Zhi. 2022 Apr 20;25(4):278-286. doi: 10.3779/j.issn.1009-3419.2022.101.16.
2
Anti-Angiogenics: Their Value in Lung Cancer Therapy.抗血管生成药物：在肺癌治疗中的价值。
Oncol Res Treat. 2018;41(4):172-180. doi: 10.1159/000488119. Epub 2018 Mar 23.
3
The Role of Angiogenesis Inhibitors in the Era of Immune Checkpoint Inhibitors and Targeted Therapy in Metastatic Non-Small Cell Lung Cancer.血管生成抑制剂在免疫检查点抑制剂和靶向治疗时代的转移性非小细胞肺癌中的作用。
Curr Treat Options Oncol. 2019 Feb 18;20(3):21. doi: 10.1007/s11864-019-0617-6.
4
Anti-angiogenesis in neuroblastoma.神经母细胞瘤的抗血管生成治疗。
Crit Rev Oncol Hematol. 2013 Jun;86(3):212-21. doi: 10.1016/j.critrevonc.2012.11.004. Epub 2012 Dec 28.
5
[III. Role of Anti-Angiogenesis Therapy for Advanced Non-Small Cell Lung Cancer - Current Status and Future Challenges].[三、抗血管生成疗法在晚期非小细胞肺癌中的作用——现状与未来挑战]
Gan To Kagaku Ryoho. 2015 Aug;42(8):940-3.
6
Anti-angiogenesis: Opening a new window for immunotherapy.抗血管生成：为免疫治疗开辟新窗口。
Life Sci. 2020 Oct 1;258:118163. doi: 10.1016/j.lfs.2020.118163. Epub 2020 Jul 29.
7
Targeting angiogenesis in advanced non-small cell lung cancer.靶向治疗晚期非小细胞肺癌中的血管生成。
J Natl Compr Canc Netw. 2013 Oct 1;11(10):1235-47. doi: 10.6004/jnccn.2013.0146.
8
Angiogenesis inhibition in non-small cell lung cancer: a critical appraisal, basic concepts and updates from American Society for Clinical Oncology 2019.血管生成抑制在非小细胞肺癌中的应用：美国临床肿瘤学会 2019 年的批判性评估、基本概念和更新。
Curr Opin Oncol. 2020 Jan;32(1):44-53. doi: 10.1097/CCO.0000000000000591.
9
[Research progress of anti-angiogenic drugs in the treatment of small cell lung cancer].抗血管生成药物治疗小细胞肺癌的研究进展
Zhonghua Zhong Liu Za Zhi. 2020 Aug 23;42(8):624-628. doi: 10.3760/cma.j.cn112152-20200217-00097.
10
Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC).血管生成抑制剂在非小细胞肺癌（NSCLC）治疗中的应用
Clin Transl Oncol. 2008 Apr;10(4):198-203. doi: 10.1007/s12094-008-0182-0.
引用本文的文献
1
Cytokine Networks in Triple-Negative Breast Cancer: Mechanisms, Therapeutic Targets, and Emerging Strategies.三阴性乳腺癌中的细胞因子网络：机制、治疗靶点及新兴策略
Biomedicines. 2025 Aug 8;13(8):1945. doi: 10.3390/biomedicines13081945.
2
Bronchial artery chemoembolization in the treatment of refractory central lung cancer with atelectasis.支气管动脉化疗栓塞术治疗合并肺不张的难治性中央型肺癌
Front Oncol. 2024 Jun 12;14:1343324. doi: 10.3389/fonc.2024.1343324. eCollection 2024.
3
[Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy
in Elderly Patients with Advanced NSCLC].[程序性死亡受体1/程序性死亡配体1免疫检查点抑制剂治疗老年晚期非小细胞肺癌的现状与展望]
Zhongguo Fei Ai Za Zhi. 2024 May 20;27(5):367-375. doi: 10.3779/j.issn.1009-3419.2024.106.10.
本文引用的文献
1
Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.贝伐珠单抗联合厄洛替尼治疗中国未经治疗的EGFR突变晚期非小细胞肺癌患者（ARTEMIS-CTONG1509）：一项多中心3期研究。
Cancer Cell. 2021 Sep 13;39(9):1279-1291.e3. doi: 10.1016/j.ccell.2021.07.005. Epub 2021 Aug 12.
2
Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, December 2020, Page S1428].《“30MO ORIENT-3：一项关于信迪利单抗与多西他赛在既往治疗的晚期/转移性鳞状非小细胞肺癌（sqNSCLC）中的随机、开放标签、III期研究”撤稿声明》：[《肿瘤学年鉴》第31卷，增刊7，2020年12月，第S1428页]
Ann Oncol. 2021 Apr;32(4):576. doi: 10.1016/j.annonc.2021.01.009.
3
Phase 1b Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients With Advanced NSCLC.信迪利单抗联合安罗替尼作为晚期 NSCLC 患者一线治疗的 1b 期研究。
J Thorac Oncol. 2021 Apr;16(4):643-652. doi: 10.1016/j.jtho.2020.11.026. Epub 2021 Jan 29.
4
Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.奥希替尼联合贝伐珠单抗对比奥希替尼用于既往接受表皮生长因子受体酪氨酸激酶抑制剂治疗的 EGFR T790M 突变型非小细胞肺癌患者的疗效：西日本肿瘤学组 8715L 期随机临床试验。
JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758.
5
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.厄洛替尼联合贝伐珠单抗对比厄洛替尼单药作为 EGFR 突变阳性非鳞状非小细胞肺癌一线治疗：随机 JO25567 研究的生存随访结果。
Lung Cancer. 2021 Jan;151:20-24. doi: 10.1016/j.lungcan.2020.11.020. Epub 2020 Nov 20.
6
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.双重 EGFR-VEGF 通路抑制：EGFR 突变型 NSCLC 患者的有前途策略。
J Thorac Oncol. 2021 Feb;16(2):205-215. doi: 10.1016/j.jtho.2020.10.006. Epub 2020 Oct 20.
7
Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors.针对 FGF-2 脱靶肿瘤的双重靶向 VEGF 和 PDGF 的治疗范例。
Nat Commun. 2020 Jul 24;11(1):3704. doi: 10.1038/s41467-020-17525-6.
8
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323.多西他赛联合贝伐单抗或培美曲塞联合贝伐单抗治疗老年（≥75岁）既往未治疗的晚期非鳞状非小细胞肺癌的开放标签、多中心、随机II期研究：TORG1323
Transl Lung Cancer Res. 2020 Jun;9(3):459-470. doi: 10.21037/tlcr.2020.03.29.
9
Bevacizumab plus chemotherapy in nonsquamous non-small cell lung cancer patients with malignant pleural effusion uncontrolled by tube drainage or pleurodesis: A phase II study North East Japan Study group trial NEJ013B.贝伐珠单抗联合化疗治疗恶性胸腔积液经引流或胸膜固定术控制不佳的非鳞状非小细胞肺癌患者：东北日本研究组试验 NEJ013B 的 II 期研究。
Thorac Cancer. 2020 Jul;11(7):1876-1884. doi: 10.1111/1759-7714.13472. Epub 2020 May 18.
10
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.每周紫杉醇联合贝伐珠单抗对比多西他赛二线或三线治疗晚期非鳞状非小细胞肺癌：IFCT-1103 ULTIMATE 研究结果。
Eur J Cancer. 2020 May;131:27-36. doi: 10.1016/j.ejca.2020.02.022. Epub 2020 Apr 8.
Zotero 插件